Your briefing

SciTech Development Announces 2nd FDA Approval of a Phase 1 a/b IND For ST-001. New IND Targets the Treatment of Relapsed/Refractory Small Cell Lung Cancer Following Its Previous Approval in the Treatment of T-Cell NHL
BTL Surpasses One Million EMFACE Treatments with 70% Growth in Record Q1, Launches First Non-invasive Treatment to Reverse Under-Eye Aging